Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.

Allogeneic hematopoietic cell transplant for HIV patients with hematologic malignancies: the BMT CTN-0903/AMC-080 trial.

Ambinder RF, Wu J, Logan B, Durand CM, Shields R, Popat UR, Little RF, McMahon DK, Cyktor J, Mellors JW, Ayala E, Kaplan LD, Noy A, Jones RJ, Howard A, Forman SJ, Porter D, Arce-Lara C, Shaughnessy P, Sproat L, Hashmi SK, Mendizabal AM, Horowitz MM, Navarro WH, Alvarnas JC.

Biol Blood Marrow Transplant. 2019 Jul 4. pii: S1083-8791(19)30417-3. doi: 10.1016/j.bbmt.2019.06.033. [Epub ahead of print]

PMID:
31279752
2.

T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy.

Keller MD, Darko S, Lang H, Ransier A, Lazarski CA, Wang Y, Hanley PJ, Davila BJ, Heimall JR, Ambinder RF, Barrett AJ, Rooney CM, Heslop HE, Douek DC, Bollard CM.

Br J Haematol. 2019 Jun 20. doi: 10.1111/bjh.16053. [Epub ahead of print]

PMID:
31219185
3.

Is It Time to Revisit the Role of Allogeneic Transplantation in Lymphoma?

Shanbhag S, Wagner-Johnston N, Ambinder RF, Jones RJ.

Curr Oncol Rep. 2019 Jun 10;21(7):65. doi: 10.1007/s11912-019-0809-z. Review.

PMID:
31183579
4.

Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial.

Bolaños-Meade J, Cooke KR, Gamper CJ, Ali SA, Ambinder RF, Borrello IM, Fuchs EJ, Gladstone DE, Gocke CB, Huff CA, Luznik L, Swinnen LJ, Symons HJ, Terezakis SA, Wagner-Johnston N, Jones RJ, Brodsky RA.

Lancet Haematol. 2019 Apr;6(4):e183-e193. doi: 10.1016/S2352-3026(19)30031-6. Epub 2019 Mar 14. Erratum in: Lancet Haematol. 2019 May;6(5):e238.

PMID:
30878319
5.

AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, Carchman E, Cohen A, Crysler OV, Gupta N, Gustafson C, Hall A, Johung KL, Klopp A, LaCasce AS, Lin C, Mehta A, Menon MP, Morgan D, Nathwani N, Noy A, Ratner L, Rizza S, Rudek MA, Sanchez J, Taylor J, Tomlinson B, Wang CJ, Yendamuri S, Dwyer MA; CGC, Freedman-Cass DA.

J Natl Compr Canc Netw. 2019 Feb;17(2):171-189. doi: 10.6004/jnccn.2019.0008.

PMID:
30787130
6.

R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma.

Messmer M, Tsai HL, Varadhan R, Swinnen LJ, Jones RJ, Ambinder RF, Shanbhag SP, Borowitz MJ, Wagner-Johnston N.

Leuk Lymphoma. 2019 May;60(5):1261-1265. doi: 10.1080/10428194.2018.1519812. Epub 2019 Jan 18.

PMID:
30656983
7.

Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide.

McCurdy SR, Kanakry CG, Tsai HL, Gojo I, Smith BD, Gladstone DE, Bolaños-Meade J, Borrello I, Matsui WH, Swinnen LJ, Huff CA, Brodsky RA, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1128-1135. doi: 10.1016/j.bbmt.2018.12.767. Epub 2018 Dec 30.

8.

Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas.

Reid EG, Looney D, Maldarelli F, Noy A, Henry D, Aboulafia D, Ramos JC, Sparano J, Ambinder RF, Lee J, Cesarman E, Yahyaei S, Mitsuyasu R, Wachsman W; AIDS Malignancy Consortium.

Blood Adv. 2018 Dec 26;2(24):3618-3626. doi: 10.1182/bloodadvances.2018022095.

9.

Prevalence of HIV in Patients with Malignancy and of Malignancy in HIV Patients in a Tertiary Care Center from North India.

Sinha S, Agarwal A, Gupta K, Mandal D, Jain M, Detels R, Nandy K, DeVos MA, Sharma SK, Manoharan N, Julka PK, Rath GK, Ambinder RF, Mitsuyasu RT.

Curr HIV Res. 2018;16(4):315-320. doi: 10.2174/1570162X16666181018161616.

10.

Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide.

Schoch LK, Cooke KR, Wagner-Johnston ND, Gojo I, Swinnen LJ, Imus P, Fuchs EJ, Levis M, Ambinder RF, Jones RJ, Gladstone DE.

Blood Adv. 2018 Sep 11;2(17):2226-2229. doi: 10.1182/bloodadvances.2018019208.

11.

Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.

Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, Carchman E, Cohen A, Gupta N, Johung KL, Klopp A, LaCasce AS, Lin C, Makarova-Rusher OV, Mehta A, Menon MP, Morgan D, Nathwani N, Noy A, Palella F, Ratner L, Rizza S, Rudek MA, Taylor J, Tomlinson B, Wang CJ, Dwyer MA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Aug;16(8):986-1017. doi: 10.6004/jnccn.2018.0066.

PMID:
30099375
12.

Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes.

McCurdy SR, Muth ST, Tsai HL, Symons HJ, Huff CA, Matsui WH, Borrello I, Gladstone DE, Swinnen LJ, Cooke KR, Brodsky RA, Bolaños-Meade J, Ambinder RF, Varadhan R, Luznik L, Jones RJ, Bettinot MP, Fuchs EJ.

Biol Blood Marrow Transplant. 2018 Oct;24(10):2056-2064. doi: 10.1016/j.bbmt.2018.06.004. Epub 2018 Jun 15.

13.

A viral protein kinase drug target for tumors?

Ambinder RF.

J Clin Invest. 2018 Jun 1;128(6):2197-2198. doi: 10.1172/JCI121080. Epub 2018 May 7.

14.

HIV-Specific T Cells Generated from Naive T Cells Suppress HIV In Vitro and Recognize Wide Epitope Breadths.

Patel S, Chorvinsky E, Albihani S, Cruz CR, Jones RB, Shpall EJ, Margolis DM, Ambinder RF, Bollard CM.

Mol Ther. 2018 Jun 6;26(6):1435-1446. doi: 10.1016/j.ymthe.2018.04.009. Epub 2018 Apr 12.

15.

Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone.

Dugan JP, Haverkos BM, Villagomez L, Martin LK, Lustberg M, Patton J, Martin M, Huang Y, Nuovo G, Yan F, Cavaliere R, Fingeroth J, Kenney SC, Ambinder RF, Lozanski G, Porcu P, Caligiuri MA, Baiocchi RA.

Clin Cancer Res. 2018 Jul 15;24(14):3273-3281. doi: 10.1158/1078-0432.CCR-17-2685. Epub 2018 Apr 9.

16.

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.

Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Armand P, Bello CM, Benitez CM, Bierman PJ, Chen R, Dabaja B, Dean R, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maddocks K, Maloney DG, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Rabinovitch R, Seropian S, Tao R, Winter JN, Yahalom J, Burns JL, Ogba N.

J Natl Compr Canc Netw. 2018 Mar;16(3):245-254. doi: 10.6004/jnccn.2018.0013.

PMID:
29523663
17.

Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors.

Elmariah H, Kasamon YL, Zahurak M, Macfarlane KW, Tucker N, Rosner GL, Bolaños-Meade J, Fuchs EJ, Wagner-Johnston N, Swinnen LJ, Huff CA, Matsui WH, Gladstone DE, McCurdy SR, Borrello I, Gocke CB, Shanbhag S, Cooke KR, Ali SA, Brodsky RA, DeZern AE, Luznik L, Jones RJ, Ambinder RF.

Biol Blood Marrow Transplant. 2018 May;24(5):1099-1102. doi: 10.1016/j.bbmt.2018.02.005. Epub 2018 Feb 13.

18.

Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075).

Ramos JC, Sparano JA, Rudek MA, Moore PC, Cesarman E, Reid EG, Henry D, Ratner L, Aboulafia D, Lee JY, Ambinder RF, Mitsuyasu R, Noy A.

Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):180-190.e2. doi: 10.1016/j.clml.2018.01.004. Epub 2018 Feb 2.

19.

Resistance Is Futile: Engineering the Adoptive T-Cell Therapies of the Future.

Shenderov E, Ambinder RF.

J Clin Oncol. 2018 Apr 10;36(11):1140-1142. doi: 10.1200/JCO.2017.76.6618. Epub 2018 Jan 24. No abstract available.

PMID:
29364774
20.

Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.

Kasamon YL, Fuchs EJ, Zahurak M, Rosner GL, Symons HJ, Gladstone DE, Huff CA, Swinnen LJ, Brodsky RA, Matsui WH, Borrello I, Shanbhag S, Cooke KR, Ambinder RF, Luznik L, Bolaños-Meade J, Jones RJ.

Biol Blood Marrow Transplant. 2018 May;24(5):1022-1028. doi: 10.1016/j.bbmt.2018.01.011. Epub 2018 Jan 17.

21.

Treatment of HIV-Associated Lymphomas: The Latest Approaches for Optimizing Outcomes.

Hunter NB, Vogt S, Ambinder RF.

Oncology (Williston Park). 2017 Dec 15;31(12):872-7, 884. Review.

22.

Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy.

Duffield AS, Ascierto ML, Anders RA, Taube JM, Meeker AK, Chen S, McMiller TL, Phillips NA, Xu H, Ogurtsova A, Berger AE, Pardoll DM, Topalian SL, Ambinder RF.

Blood Adv. 2017 Jul 21;1(17):1324-1334. doi: 10.1182/bloodadvances.2017007260. eCollection 2017 Jul 25.

23.

Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma.

Welch JJG, Schwartz CL, Higman M, Chen L, Buxton A, Kanakry JA, Kahwash SB, Hutchison RE, Friedman DL, Ambinder RF.

Blood Adv. 2017 Apr 24;1(11):681-684. doi: 10.1182/bloodadvances.2016002618. eCollection 2017 Apr 25.

24.

Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas.

Li L, Xu J, Qiu G, Ying J, Du Z, Xiang T, Wong KY, Srivastava G, Zhu XF, Mok TS, Chan AT, Chan FK, Ambinder RF, Tao Q.

Theranostics. 2018 Jan 1;8(1):61-77. doi: 10.7150/thno.20893. eCollection 2018.

25.

Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide.

Kasamon YL, Ambinder RF, Fuchs EJ, Zahurak M, Rosner GL, Bolaños-Meade J, Levis MJ, Gladstone DE, Huff CA, Swinnen LJ, Matsui WH, Borrello I, Brodsky RA, Jones RJ, Luznik L.

Blood Adv. 2017;1(4):288-292. doi: 10.1182/bloodadvances.2016002766. Epub 2017 Jan 6.

26.

Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients.

Schoch LK, Asiama A, Zahurak M, Shanbhag S, Hurtt J, Sawyer K, Swinnen LJ, Wagner-Johnston N, Jones RJ, Ambinder RF, Gladstone DE.

Cancer Chemother Pharmacol. 2018 Feb;81(2):347-354. doi: 10.1007/s00280-017-3499-y. Epub 2017 Dec 13.

PMID:
29234922
27.

Hodgkin lymphoma: A review and update on recent progress.

Shanbhag S, Ambinder RF.

CA Cancer J Clin. 2018 Mar;68(2):116-132. doi: 10.3322/caac.21438. Epub 2017 Dec 1. Review.

28.

Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide.

McCurdy SR, Kanakry CG, Tsai HL, Kasamon YL, Showel MM, Bolaños-Meade J, Huff CA, Borrello I, Matsui WH, Brodsky RA, Ambinder RF, Bettinotti MP, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Biol Blood Marrow Transplant. 2018 Feb;24(2):343-352. doi: 10.1016/j.bbmt.2017.10.023. Epub 2017 Oct 18.

29.

Plasma Epstein-Barr Virus DNA for Screening.

Ambinder RF.

N Engl J Med. 2017 Aug 10;377(6):584-585. doi: 10.1056/NEJMe1706815. No abstract available.

PMID:
28792884
30.

Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation.

Imus PH, Blackford AL, Bettinotti M, Iglehart B, Dietrich A, Tucker N, Symons H, Cooke KR, Luznik L, Fuchs EJ, Brodsky RA, Matsui WH, Huff CA, Gladstone D, Ambinder RF, Borrello IM, Swinnen LJ, Jones RJ, Bolaños-Meade J.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1887-1894. doi: 10.1016/j.bbmt.2017.07.014. Epub 2017 Jul 25.

31.

Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma.

Ghosh N, Ye X, Tsai HL, Bolaños-Meade J, Fuchs EJ, Luznik L, Swinnen LJ, Gladstone DE, Ambinder RF, Varadhan R, Shanbhag S, Brodsky RA, Borrello IM, Jones RJ, Matsui W, Huff CA.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1903-1909. doi: 10.1016/j.bbmt.2017.07.003. Epub 2017 Jul 12.

32.

Drug Modulators of B Cell Signaling Pathways and Epstein-Barr Virus Lytic Activation.

Kosowicz JG, Lee J, Peiffer B, Guo Z, Chen J, Liao G, Hayward SD, Liu JO, Ambinder RF.

J Virol. 2017 Jul 27;91(16). pii: e00747-17. doi: 10.1128/JVI.00747-17. Print 2017 Aug 15.

33.

High frequency of identical clonal immunoglobulin DNA in pre-treatment tumor and plasma from untreated patients with HIV-associated lymphoma: prospective multicenter trial of the AIDS malignancies consortium (AMC 064).

Wagner-Johnston ND, Lensing S, Noy A, Ratner L, Henry D, Lee JY, Silver S, Faham M, Ambinder RF.

Leuk Lymphoma. 2017 Dec;58(12):2939-2942. doi: 10.1080/10428194.2017.1317095. Epub 2017 May 16.

34.

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bernat K, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Smith M, Winter JN, Yahalom J, Burns J, Ogba N, Sundar H.

J Natl Compr Canc Netw. 2017 May;15(5):608-638.

PMID:
28476741
35.

Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis.

Levin LI, Breen EC, Birmann BM, Batista JL, Magpantay LI, Li Y, Ambinder RF, Mueller NE, Martínez-Maza O.

Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1114-1123. doi: 10.1158/1055-9965.EPI-16-1012. Epub 2017 Mar 24.

36.

Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity.

Martin AR, Pollack RA, Capoferri A, Ambinder RF, Durand CM, Siliciano RF.

J Clin Invest. 2017 Feb 1;127(2):651-656. doi: 10.1172/JCI89552. Epub 2017 Jan 17.

37.

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.

Kanakry CG, Bolaños-Meade J, Kasamon YL, Zahurak M, Durakovic N, Furlong T, Mielcarek M, Medeot M, Gojo I, Smith BD, Kanakry JA, Borrello IM, Brodsky RA, Gladstone DE, Huff CA, Matsui WH, Swinnen LJ, Cooke KR, Ambinder RF, Fuchs EJ, de Lima MJ, Andersson BS, Varadhan R, O'Donnell PV, Jones RJ, Luznik L.

Blood. 2017 Mar 9;129(10):1389-1393. doi: 10.1182/blood-2016-09-737825. Epub 2017 Jan 3.

38.

Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy.

Lee JY, Dhakal I, Casper C, Noy A, Palefsky JM, Haigentz M, Krown SE, Ambinder RF, Mitsuyasu RT.

J Cancer Epidemiol. 2016;2016:2138259. Epub 2016 Nov 2.

39.

Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.

McCurdy SR, Kasamon YL, Kanakry CG, Bolaños-Meade J, Tsai HL, Showel MM, Kanakry JA, Symons HJ, Gojo I, Smith BD, Bettinotti MP, Matsui WH, Dezern AE, Huff CA, Borrello I, Pratz KW, Gladstone DE, Swinnen LJ, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Haematologica. 2017 Feb;102(2):391-400. doi: 10.3324/haematol.2016.144139. Epub 2016 Oct 20.

40.

Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma.

Jacene H, Crandall J, Kasamon YL, Ambinder RF, Piantadosi S, Serena D, Kasecamp W, Wahl RL.

Mol Imaging Biol. 2017 Jun;19(3):429-436. doi: 10.1007/s11307-016-1019-9.

PMID:
27798787
41.

Corrigendum: Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers.

Li L, Li C, Mao H, Du Z, Chan WY, Murray P, Luo B, Chan AT, Mok TS, Chan FK, Ambinder RF, Tao Q.

Sci Rep. 2016 Oct 6;6:34435. doi: 10.1038/srep34435. No abstract available.

42.

Tumor-Infiltrating Macrophages in Post-Transplant, Relapsed Classical Hodgkin Lymphoma Are Donor-Derived.

Crane GM, Samols MA, Morsberger LA, Yonescu R, Thiess ML, Batista DA, Ning Y, Burns KH, Vuica-Ross M, Borowitz MJ, Gocke CD, Ambinder RF, Duffield AS.

PLoS One. 2016 Sep 29;11(9):e0163559. doi: 10.1371/journal.pone.0163559. eCollection 2016.

43.

EBV, an inhibited receptor kinase, and lymphoma.

Ambinder RF.

Blood. 2016 Sep 22;128(12):1542-3. doi: 10.1182/blood-2016-08-724955. No abstract available.

44.

Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers.

Li L, Li C, Mao H, Du Z, Chan WY, Murray P, Luo B, Chan AT, Mok TS, Chan FK, Ambinder RF, Tao Q.

Sci Rep. 2016 May 26;6:26591. doi: 10.1038/srep26591. Erratum in: Sci Rep. 2016 Oct 06;6:34435.

45.

The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases.

Kanakry JA, Hegde AM, Durand CM, Massie AB, Greer AE, Ambinder RF, Valsamakis A.

Blood. 2016 Apr 21;127(16):2007-17. doi: 10.1182/blood-2015-09-672030. Epub 2016 Jan 7.

46.

Functionally Active HIV-Specific T Cells that Target Gag and Nef Can Be Expanded from Virus-Naïve Donors and Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic Hematopoietic Stem Cell Transplantation.

Patel S, Lam S, Cruz CR, Wright K, Cochran C, Ambinder RF, Bollard CM.

Biol Blood Marrow Transplant. 2016 Mar;22(3):536-41. doi: 10.1016/j.bbmt.2015.12.007. Epub 2015 Dec 22.

47.

Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059.

Bender Ignacio RA, Lee JY, Rudek MA, Dittmer DP, Ambinder RF, Krown SE; AIDS Malignancy Consortium (AMC)-059 Study Team.

J Acquir Immune Defic Syndr. 2016 May 1;72(1):52-7. doi: 10.1097/QAI.0000000000000918.

48.

Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage.

Crane GM, Powell H, Kostadinov R, Rocafort PT, Rifkin DE, Burger PC, Ambinder RF, Swinnen LJ, Borowitz MJ, Duffield AS.

Oncotarget. 2015 Oct 20;6(32):33849-66. doi: 10.18632/oncotarget.5292.

49.

Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation.

Lee HG, Kim H, Kim EJ, Park PG, Dong SM, Choi TH, Kim H, Chong CR, Liu JO, Chen J, Ambinder RF, Hayward SD, Park JH, Lee JM.

Oncotarget. 2015 Oct 13;6(31):31018-29. doi: 10.18632/oncotarget.5041.

50.

Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).

Epeldegui M, Lee JY, Martínez AC, Widney DP, Magpantay LI, Regidor D, Mitsuyasu R, Sparano JA, Ambinder RF, Martínez-Maza O.

Clin Cancer Res. 2016 Jan 15;22(2):328-36. doi: 10.1158/1078-0432.CCR-14-0466. Epub 2015 Sep 17.

Supplemental Content

Loading ...
Support Center